Syndax(US:SNDX)2026-02-26 21:04Financial Performance - Revuforj generated net product revenue of $124.8 million for the year ended December 31, 2025, compared to $7.7 million for 2024, with no revenue in 2023 [358][359]. - The company reported a net loss of $285.4 million for the year ended December 31, 2025, compared to a net loss of $318.8 million in 2024 and $209.4 million in 2023 [355]. - Total revenue for 2025 reached $172.4 million, up from $23.7 million in 2024, marking an increase of $148.7 million [387]. - Collaboration revenue for the year ended December 31, 2025, was $42.4 million, with no collaboration revenue reported in 2024 as Niktimvo launched in January 2025 [389]. - The company reported a net loss of $285.4 million for the year ended December 31, 2025, an improvement from a net loss of $318.8 million in 2024 [387]. Cash and Investments - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $394.1 million, expected to fund operations for at least the next 12 months [400]. - Net cash provided by investing activities for the year ended December 31, 2025, was $290.0 million, primarily from $486.0 million in proceeds from the maturities of available-for-sale marketable securities [416]. - The company has established guidelines regarding approved investments and maturities of investments to maintain safety and liquidity, with cash and short-term investments totaling $394.1 million as of December 31, 2025 [423]. Operating Expenses - Total operating expenses increased to $445.4 million in 2025 from $363.4 million in 2024, an increase of $82.1 million [387]. - Research and development expenses rose to $258.8 million in 2025, up by $17.1 million from $241.6 million in 2024, primarily due to increased costs associated with clinical trials [394]. - Selling, general and administrative expenses increased by $58.8 million to $179.7 million in 2025, driven by higher personnel costs and marketing activities [396]. Future Outlook and Strategy - The company plans to continue leveraging its management team's expertise to license, acquire, and develop additional therapeutics to expand its pipeline [354]. - Future funding requirements will be supported by expected product revenues and collaboration revenue, with primary uses of capital including clinical research and commercialization costs [405]. - The company expects to support future cash needs through product sales, equity offerings, debt financings, and additional funding from license and collaboration arrangements [408]. Regulatory and Market Developments - Niktimvo sales began in February 2025 after receiving FDA approval in August 2024 for the treatment of chronic graft-versus-host disease [360][353]. - Revuforj was approved by the FDA in November 2024 for treating relapsed or refractory acute leukemia with specific genetic mutations [352]. - Collaboration revenue from Incyte will be recognized as the company shares profits or losses from the commercialization of Niktimvo [361]. Risks and Challenges - The company is subject to risks including high interest rates, economic uncertainty, and potential inflationary pressures that could impact operating costs [356][357]. - As of December 31, 2025, the company had an accumulated deficit of $1.5 billion and anticipates continuing to incur significant losses in the near future [410]. - The company does not believe that inflation and changing prices had a significant impact on its results of operations for any periods presented [424].